Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
Tudor-Eliade Ciuleanu
No relevant relationships to disclose
Igor Bazin
Research Funding - Federal State Budgetary Institution, Russian Oncology Research Center
Dan Lungulescu
Research Funding - DERMA 111982
Lucian Miron
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Andrzej Deptala
Honoraria - Bayer
Maribel Rodriguez-Torres
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Janssen Research & Development; Merck Sharp & Dohme; Roche; Santaris; SCYNEXIS Inc.; Vertex
Research Funding - AbbVie; Beckman Coulter; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Gilead Sciences; GlaxoSmithKline; Human Genome Sciences; Idenix; Idera; Johnson & Johnson; Merck Sharp & Dohme; Mochida Pharmaceutical Co. Ltd.; Novartis; Pfizer; Roche; Santaris; SCYNEXIS Inc.; Siemens Healthcare Diagnostics; Vertex; Zymogenetics
Bruce J. Giantonio
No relevant relationships to disclose
Weijing Sun
No relevant relationships to disclose
Norma Lynn Fox
Employment or Leadership Position - GlaxoSmithKline; Human Genome Sciences
Stock Ownership - GlaxoSmithKline; Human Genome Sciences
Gursel Aktan
Employment or Leadership Position - GlaxoSmithKline (B)
Stock Ownership - GlaxoSmithKline (B)
Paul Stephen Wissel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Jacki Egger
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Meichun Ding
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Rubana Kalyani
Employment or Leadership Position - GlaxoSmithKline
Matthew Joseph Gribbin
Employment or Leadership Position - Human Genome Sciences